U.S., Oct. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07870265) titled 'Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System' on Oct. 06.
Brief Summary: The goal of this prospective, low-interventional study is to develop and optimize a highly sensitive and specific method for the detection of the BRAF V600E mutation in liquid biopsy samples from patients with unresectable metastatic melanoma after disease relapse. The method will be based on a CRISPR/Cas12a system combined with isothermal amplification and endpoint electrochemical detection using electrode chips and low-cost instrumentation.
Study Start Date: Oct. 20
Study Type: INTERVENTIONAL
Condition:
Unresectable...